Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life
NCT ID: NCT01595724
Last Updated: 2015-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3006 participants
OBSERVATIONAL
2012-05-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis
NCT02425462
A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
NCT04808843
Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients
NCT01822080
A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants
NCT04495855
Regulatory Post Marketing Surveillance Study in Korea
NCT01788722
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Visanne (Dienogest, BAY86-5258)
Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Visanne (Dienogest, BAY86-5258)
Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical or laparoscopic diagnosis of endometriosis
* Having endometriosis related pain as leading symptom
* Decision taken by physician to prescribe Visanne
* Signed Informed Consent Form
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Belarus
Many Locations, , Egypt
Many Locations, , Jordan
Many Locations, , Kazakhstan
Many Locations, , Kuwait
Many Locations, , Lebanon
Many Locations, , Qatar
Many Locations, , Russia
Many Locations, , Saudi Arabia
Many Locations, , Ukraine
Many Locations, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VS1101
Identifier Type: OTHER
Identifier Source: secondary_id
16108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.